drugset / Trial / NCT05620680
CD7 CAR-T Cells in T-cell Lymphoma/Leukemia
NaSingle-groupOpen-labelTreatment
Summary
T-cell lymphoma/leukemia is a group of highly lethal diseases with a high relapse rate and poor prognosis. CD7 was proved to be widely expressed in T-cell malignant, which makes it a promising therapeutic target. In this study we aim to test the safety and efficacy of CD7 CAR-T cells in T-cell lymphoma/leukemia.
Timeline
- Start
- 2022-10-01
- Primary completion
- 2026-10-31
- Completion
- 2028-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD7 CAR-T cells | Cell therapy | 500000 cells/kg | — |
| Subject | CD7 CAR-T cells | Cell therapy | 2e+06 cells/kg | — |